Phillips, Elizabeth J, Sukasem, Chonlaphat, Whirl-Carrillo, Michelle, Mueller, Daniel J, Dunnenberger, Henry M, Chantratita, Wasun, Goldspiel, Barry, Chen, Yuan-Tsong, Carleton, Bruce C, George, Alfred L et al (show 4 more authors)
(2018)
Clinical Pharmacogenetics Implementation Consortium Guideline for <i>HLA</i> Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 103 (4).
pp. 574-581.
Text
HLA_CBZ_OXC CPIC Guideline_10.13.2017 (FINAL-NO TABLES)_REVISED-CLEAN (FINAL).docx - Author Accepted Manuscript Download (111kB) |
|
Text
HLA_CBZ_OXC CPIC Guideline Supplement_10.13.2017 (FINAL)_REVISED.docx - Author Accepted Manuscript Download (233kB) |
|
Text
HLA_CBZ_OXC CPIC Guideline TABLE 1 FINAL.docx - Author Accepted Manuscript Download (12kB) |
|
Text
HLA_CBZ_OXC CPIC Guideline TABLE 2 FINAL.docx - Author Accepted Manuscript Download (16kB) |
|
Text
HLA_CBZ_OXC CPIC Guideline TABLE 3 FINAL.docx - Author Accepted Manuscript Download (13kB) |
Abstract
The variant allele HLA-B*15:02 is strongly associated with greater risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in patients treated with carbamazepine or oxcarbazepine. The variant allele HLA-A*31:01 is associated with greater risk of maculopapular exanthema, drug reaction with eosinophilia and systemic symptoms, and SJS/TEN in patients treated with carbamazepine. We summarize evidence from the published literature supporting these associations and provide recommendations for carbamazepine and oxcarbazepine use based on HLA genotypes.
Item Type: | Article |
---|---|
Uncontrolled Keywords: | Humans, Carbamazepine, Anticonvulsants, HLA-B Antigens, Pharmacogenetics, Drug-Related Side Effects and Adverse Reactions, Oxcarbazepine |
Depositing User: | Symplectic Admin |
Date Deposited: | 25 Apr 2018 06:33 |
Last Modified: | 13 Oct 2023 13:04 |
DOI: | 10.1002/cpt.1004 |
Related URLs: | |
URI: | https://livrepository.liverpool.ac.uk/id/eprint/3020562 |